Rep. Gilbert Ray Cisneros, Jr. Buys Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in Ultragenyx Pharmaceutical stock on March 3rd. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded down $0.61 during trading on Friday, hitting $23.30. The stock had a trading volume of 1,551,092 shares, compared to its average volume of 2,096,833. The company has a market capitalization of $2.29 billion, a PE ratio of -3.99 and a beta of 0.25. The company’s 50-day moving average price is $22.09 and its two-hundred day moving average price is $27.57. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm had revenue of $207.28 million during the quarter, compared to the consensus estimate of $199.60 million. During the same quarter in the previous year, the firm posted ($1.39) EPS. The company’s revenue was up 25.5% on a year-over-year basis. As a group, equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on RARE shares. Canaccord Genuity Group dropped their price objective on Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Bank of America dropped their price objective on Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. HC Wainwright dropped their price objective on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 21st. Finally, JPMorgan Chase & Co. dropped their price objective on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a research note on Thursday, March 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.47.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RARE. Jacobs Levy Equity Management Inc. increased its holdings in shares of Ultragenyx Pharmaceutical by 614.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company’s stock worth $65,205,000 after acquiring an additional 1,864,164 shares during the last quarter. Norges Bank acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth approximately $29,004,000. Millennium Management LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 787.6% during the 4th quarter. Millennium Management LLC now owns 880,644 shares of the biopharmaceutical company’s stock worth $20,255,000 after acquiring an additional 781,431 shares during the last quarter. Vestal Point Capital LP acquired a new position in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $22,560,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Ultragenyx Pharmaceutical by 599.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 840,451 shares of the biopharmaceutical company’s stock worth $25,281,000 after acquiring an additional 720,256 shares during the last quarter. 97.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Erik Harris sold 10,539 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total transaction of $240,289.20. Following the transaction, the executive vice president directly owned 89,515 shares of the company’s stock, valued at approximately $2,040,942. The trade was a 10.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Howard Horn sold 8,409 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $22.70, for a total value of $190,884.30. Following the transaction, the chief financial officer directly owned 86,669 shares in the company, valued at $1,967,386.30. The trade was a 8.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 109,556 shares of company stock worth $2,490,138 in the last three months. 5.20% of the stock is owned by insiders.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.